SCHEMBL733667

SCHEMBL733667

N#CCOC(=O)CCc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
LMNA P02545 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
MAPT P10636 10/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 4/20 0.57
TDP1 Q9NUW8 2/20 0.57
GAA P10253 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
POLB P06746 1/20 0.54
TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2380211 0.91 SMN1; SMN2 (0.66) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2378990 0.90 SMN1; SMN2 (0.65) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL392573 0.82 SMN1; SMN2 (0.85) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL22076496 0.82 MAPT (0.67) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL10676155 0.80 SMN1; SMN2 (0.68) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4071928 0.80 LMNA (0.70) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
Methyl 3-(3-Indolylmethyl)Propanoate SCHEMBL290808 0.79 MAPT (0.71) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1520024 0.79 MAPT (0.64) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19426752 0.79 MAPT (0.63) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL21819666 0.78 MAPT (0.62) SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101516844-B 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems GRUENENTHAL GMBH 2013-12-11 CN disclosed
US-8138187-B2 Substituted heteroaryl derivatives GRUENENTHAL GMBH (DE) 2012-03-20 US disclosed
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES GRUNENTHAL GMBH (DE) 2010-01-14 US disclosed
CN-101516844-A 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems GRUENENTHAL GMBH (DE) 2009-08-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES CYP3A43, HMGCR, ABCG2 SMN1; SMN2 4848/4885CYP1A2 29/4885CYP3A4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.